



⑪ Publication number : **0 670 370 A2**

EUROPEAN PATENT APPLICATION

⑫
②① Application number : **95100259.1**

②② Date of filing : **10.01.95**

⑤① Int. Cl.⁶ : **C12N 15/52, C12P 13/14,
C12N 1/21, // (C12N1/21,
C12R1:19)**

③⑩ Priority : **10.01.94 JP 825/94**

④③ Date of publication of application :
06.09.95 Bulletin 95/36

⑥④ Designated Contracting States :
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

⑦① Applicant : **Ajinomoto Co., Inc.**
No. 15-1, Kyobashi 1-chome,
Chuo-ku
Tokyo 104 (JP)

⑦② Inventor : **Ono, Eiji, c/o Central Research**
Laboratories
Ajinomoto Co., Inc.,
No. 1-1 Suzuki-cho
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken
(JP)

Inventor : Tsujimoto, Nobuharu, c/o Central
Research Lab.
Ajinomoto Co., Inc.,
No. 1-1 Suzuki-cho
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken
(JP)

Inventor : Matsui, Kazuhiko, c/o Central
Research Lab.
Ajinomoto Co., Inc.,
No. 1-1 Suzuki-cho
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken
(JP)

Inventor : Kurahashi, Osamu, c/o Central
Research Lab.
Ajinomoto Co., Inc.,
No. 1-1 Suzuki-cho
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken
(JP)

⑦④ Representative : **Strehl Schübel-Hopf Groening**
& Partner
Maximilianstrasse 54
D-80538 München (DE)

⑤④ **Method of producing L-glutamic acid by fermentation.**

⑤⑦ The present invention provides a low-cost and efficient production method of L-glutamic acid, by improving the productivity of L-glutamic acid in a microorganism of the genus Escherichia.
[Constitution]

A method of producing L-glutamic acid by fermentation comprising culturing in a liquid culture medium a mutant of the genus Escherichia having L-glutamic acid-producing ability whose α -ketoglutarate dehydrogenase activity is deficient or reduced and phosphoenolpyruvate carboxylase and glutamate dehydrogenase activities are amplified, accumulating L-glutamic acid in the culture, and recovering L-glutamic acid therefrom.

Field of the Invention

The present invention relates to a mutant useful for producing L-glutamic acid by fermentation as well as a method of producing L-glutamic acid by fermentation using such a mutant. L-glutamic acid is an amino acid widely used as an additive for foods and in medicaments.

Prior Art

L-glutamic acid has conventionally been produced by fermentation using glutamic acid-producing bacteria and mutants thereof such as those of the genus Brevibacterium, Corynebacterium or Microbacterium (Amino acid fermentation, Gakkai Shuppan Center, pp.195 to 215 (1986)). Other known methods of producing L-glutamic acid by fermentation include a method employing microorganisms of the genus Bacillus, Streptomyces or Penicillium (US Patent No. 3,220,929) and a method employing microorganisms of the genus Pseudomonas, Arthrobacter, Serratia or Candida (US Patent No. 3,563,857). Even though such conventional methods produce significantly large amounts of L-glutamic acid, an even more efficient and less expensive method of producing L-glutamic acid is desired in order to meet the ever-increasing demand.

Escherichia coli is a potentially excellent L-glutamic acid-producing bacterium in view of its high growth rate and the availability of sufficient gene information, while the reported amount of L-glutamic acid production by Escherichia coli is as low as 2.3 g/l (J. Biochem., Vol. 50, pp.164 to 165 (1961)). Recently, a mutant exhibiting a deficient or reduced α -ketoglutarate dehydrogenase (hereinafter referred to as α -KGDH) was reported to have the ability to produce large amounts of L-glutamic acid (French Patent Application Laid-Open No. 2680178).

Problems to be Solved by the Invention

An objective of the present invention is to enhance the L-glutamic acid-producing ability of strains belonging to the genus Escherichia and to provide a method of producing L-glutamic acid more efficiently and at a lower cost.

Means to Solve the Problems

Now it has been found surprisingly in our study on the production of L-glutamic acid by mutants of Escherichia coli that a mutant whose α -KGDH activity is deficient or reduced, and whose phosphoenolpyruvate carboxylase (hereinafter referred to as PPC) and glutamate dehydrogenase (hereinafter referred to as GDH) activities are enhanced, has a high L-glutamic acid-producing ability, and thus the present invention has been accomplished.

Accordingly, the present invention relates to :

A mutant of the genus Escherichia having L-glutamic acid-producing ability whose α -KGDH activity is deficient or reduced, and PPC and GDH activities are enhanced; and,

A method of producing L-glutamic acid by fermentation comprising culturing in a liquid culture medium a mutant of the genus Escherichia having L-glutamic acid-producing ability whose α -KGDH activity is deficient or reduced and PPC and GDH activities are enhanced, accumulating L-glutamic acid in the culture, and recovering L-glutamic acid therefrom.

The present invention is described in more detail below.

(1) Derivation of a mutant of the genus Escherichia exhibiting deficient or reduced α -KGDH activity

As a starting parent strain to be used for preparing the present mutant, any non-pathogenic strain of the genus Escherichia may be employed. Examples of such strains are listed below.

Escherichia coli K-12 (ATCC 10798)

Escherichia coli W3110 (ATCC 27325)

Escherichia coli B (ATCC 11303)

Escherichia coli W (ATCC 9637)

A mutant of the genus Escherichia which has L-glutamic acid-producing ability and having deficient or reduced α -KGDH activity may be prepared as follows.

The starting parent strain mentioned above is first exposed to X-radiation or ultraviolet light or mutagenic agents such as N-methyl-N'-nitro-N-nitrosoguanidine (hereinafter referred to as NG) to introduce the mutation.

Alternatively, gene engineering technology, for example, gene recombination, gene transformation or cell

fusion, may be used to efficiently introduce the intended mutation.

A method of obtaining an α -KGDH-deficient mutant by means of gene recombination is conducted as follows. Based on the known nucleotide sequence (Euro. J. Biochem. Vol. 141, pp. 351 to 359 (1984)) of α -ketoglutarate dehydrogenase gene (hereinafter referred to as sucA gene), primers are synthesized and then the sucA gene is amplified by the PCR method using the chromosomal DNA as a template. Into the amplified the sucA gene, a drug-resistant gene is inserted to obtain a sucA gene whose function is lost. Subsequently, using homologous recombination, the sucA gene on the chromosome is replaced by a sucA gene whose function is lost by means of the insertion of the drug-resistant gene.

After subjecting the parent strain to mutagenic treatment, the intended mutants may be screened by procedures as illustrated below.

A mutant exhibiting a deficient or reduced α -KGDH activity is either not able to grow or is able to grow only at a significantly reduced growth rate in a minimum culture medium containing glucose as the carbon source under aerobic condition. However, even under such condition, normal growth is possible by adding succinic acid or lysine plus methionine to the minimum culture medium containing glucose. On the other hand, anaerobic condition allows the mutant to grow even in the minimum culture medium containing glucose (Molec. Gen. Genetics, Vol. 105, pp. 182 to 190 (1969)). Based on these findings, the desired mutants can be screened.

The following strain is an example of the mutants thus obtained whose α -KGDH activity is deficient or reduced and which are listed below.

Escherichia coli W3110 sucA::Km^r

A mutant whose α -KGDH activity is deficient or reduced is more useful in view of its enhanced ability to produce L-glutamic acid when it further has the properties that L-glutamic acid-degrading activity is reduced or the expression of ace operon, that is, malate synthase (aceB) - isocitrate lyase (aceA) - isocitrate dehydrogenase kinase/phosphatase (aceK) operon becomes constitutive. These properties are discussed in French Patent Application Laid-open No. 2680178. As a matter of course, properties already known to be effective for improving L-glutamic acid-productivity, such as various types of auxotrophy, antimetabolite resistance and antimetabolite sensitivity, are also desirable for enhancing L-glutamic acid production ability.

A mutant having reduced ability to degrade L-glutamic acid may be isolated as a mutant which either cannot grow or can grow only slightly in a minimum culture medium containing L-glutamic acid as the sole carbon source instead of glucose or containing L-glutamic acid as a sole nitrogen source instead of ammonium sulfate. However, as a matter of course, when an auxotroph is employed for the derivation, the minimum essential amount of the nutrient required for the growth may be added to the culture medium.

A mutant in which the expression of the ace operon is constitutive may be obtained as a strain whose parent strain is a phosphoenolpyruvate synthase-deficient strain and which can grow in a minimum culture medium containing lactic acid as the carbon source but cannot grow in a minimum culture medium containing pyruvic acid or acetic/pyruvic acid as the carbon source, or as a strain which shows a higher growth rate than that of its parent strain whose α -KGDH is deficient or reduced under aerobic condition (J. Bacteriol., Vol. 96, pp. 2185 to 2186 (1968)).

Examples of the mutants described above are as follows.

Escherichia coli AJ 12628 (FERM BP-3854)

Escherichia coli AJ 12624 (FERM BP-3853)

Escherichia coli AJ 12628 is a mutant having a reduced α -KGDH activity and a reduced ability to degrade L-glutamic acid in combination with constitutive expression of ace operon. Escherichia coli AJ 12624 is a mutant having reduced α -KGDH activity and a reduced ability to degrade L-glutamic acid (French Patent Application Laid-open No. 2680178).

In the mutant thus obtained which exhibits deficient or reduced α -KGDH activity, the flow of biosynthesis of L-glutamic acid via α -ketoglutaric acid in the TCA cycle is improved, resulting in an enhanced ability of producing L-glutamic acid. Also the productivity of L-glutamic acid is increased in the mutant exhibiting deficient or reduced α -KGDH activity and significantly low ability to degrade the produced L-glutamic acid or in the mutant further having a constitutive expression of the ace operon whereby the growth is improved.

(2) Derivation of a mutant of the genus Escherichia having amplified PPC activity and GDH activity

In the examples described below, a mutant of the genus Escherichia having amplified PPC and GDH activities was obtained from a starting parent strain exhibiting deficient or reduced α -KGDH activity and having the ability to produce L-glutamic acid. It is also possible to use a wild strain of the genus Escherichia as the parent strain to obtain a mutant having amplified PPC and GDH activities whereafter a mutant is bred which exhibits deficient or reduced α -KGDH activity.

Accordingly, the starting parent strain used to prepare a mutant having amplified PPC and GDH activities

is preferably a mutant of the genus Escherichia whose α -KGDH activity is deficient or reduced and which has the ability to produce L-glutamic acid or a non-pathogenic wild type strain of the genus Escherichia. Examples of such strains are listed below.

Escherichia coli W3100 sucA::Km^r

Escherichia coli AJ 12628 (FERM BP-3854)

Escherichia coli AJ 12624 (FERM BP-3853)

(Those listed above are the mutants of the genus Escherichia whose α -KGDH activity is deficient or reduced and which have the ability to produce L-glutamic acid.)

Escherichia coli K-12 (ATCC 10798)

Escherichia coli W3110 (ATCC 27325)

Escherichia coli B (ATCC 11303)

Escherichia coli W (ATCC 9637)

(Those listed above are the non-pathogenic wild strains of the genus Escherichia.)

In order to amplify PPC and GDH activities, the genes coding for PPC and GDH are cloned in an appropriate plasmid, which is then used to transform the starting parent strain employed as a host. The copies of the genes coding for PPC and GDH (hereinafter referred to as ppc gene and gdhA gene, respectively) in the transformed cells are increased, resulting in amplified PPC and GDH activities.

The ppc gene and gdhA gene to be cloned may be cloned into a single plasmid to be introduced into the starting parent strain employed as the host, or may be cloned separately into two types of plasmid which are compatible in the starting parent strain.

Alternatively, the amplification of PPC and GDH activities may be conducted by allowing the ppc and gdhA genes to be present as multicopies on the chromosomal DNA of the starting parent strain employed as the host. In order to introduce the ppc and gdhA genes as multicopies into the chromosomal DNA of the genus Escherichia, homologous recombination is applied utilizing a target sequence present as a multicopy on the chromosomal DNA. The sequence present as the multicopy may be a repetitive DNA and an inverted repeat present at the terminal of insertion sequence. Alternatively, as described in Japanese Patent Application Laid-open No. 2-109985, the ppc and gdhA genes are cloned on a transposon, which is then transposed, thereby introducing the multicopy into the chromosomal DNA. The copies of the ppc and gdhA genes in the transformed cells are increased, resulting in the amplification of PPC and GDH activities.

In addition to the gene amplification described above, the amplification of PPC and GDH activities may also be conducted by replacing the promoters of the ppc and gdhA genes with those having higher potencies. For example, lac promoter, trp promoter, trc promoter, tac promoter, P_R promoter and P_L promoter of a lambda phage are known to be strong promoters. By enhancing the expression of the ppc gene and of the gdhA gene, the PPC and GDH activities are amplified.

The ppc and gdhA genes can be obtained by isolating the genes which are complementary with regard to auxotrophy of the mutants which are either PPC or GDH deficient. Alternatively, since the nucleotide sequences of these genes of Escherichia coli are known (J. Biochem., Vol. 95, pp. 909 to 916 (1984); Gene, Vol. 27, pp. 193 to 199 (1984)), the primers are synthesized based on the nucleotide sequences and then the genes are obtained by the PCR method using the chromosomal DNA as the template.

(3) Production of L-glutamic acid by fermentation using a mutant of the genus Escherichia capable of producing L-glutamic acid which exhibits deficient or reduced α -KGDH activity and has amplified PPC and GDH activities

For the purpose of producing L-glutamic acid by fermentation using a mutant of the genus Escherichia capable of producing L-glutamic acid which exhibits deficient or reduced α -KGDH activity and has amplified PPC and GDH activities, a standard culture medium containing carbon sources, nitrogen sources, inorganic salts and, if necessary, organic trace nutrients such as amino acids and vitamins and a standard culture method may be employed. The carbon sources and the nitrogen sources employed in the culture medium may be any of those catabolized by the mutant employed.

The carbon sources may be saccharides such as glucos⁻, glycerol, fructose, sucrose, maltose, mannose, galactose, starch hydrolysate and molasses, and organic acids such as acetic acid and citric acid may also be employed independently or in combination with other carbon sources.

The nitrogen sources may be ammonia and ammonium salts such as ammonium sulfate, ammonium carbonate, ammonium chloride, ammonium phosphate, ammonium acetate as well as nitrates.

The organic trace nutrients may be amino acids, vitamins, fatty acids and nucleic acids as they are or as contained in peptone, casamino acid, yeast extract, soy protein hydrolysate and the like. In cases of using an auxotroph the nutrient required for its growth should be supplemented.

The inorganic salts may be phosphate, magnesium salts, calcium salts, iron salts, manganese salts and the like.

Cultivation is conducted at a fermentation temperature from 20 to 45°C at a pH controlled to be in a range of from 5 to 9 with aeration. When the pH is controlled during the cultivation, calcium carbonate or alkali such as ammonia gas may be added for neutralization. After culturing for from 10 hours to 4 days, a significant amount of L-glutamic acid is accumulated in the culture medium.

L-glutamic acid in the culture medium after cultivation may be recovered by any of the known methods. For example, the cells are removed from the culture medium, which is then concentrated and precipitated or subjected to ion exchange chromatography to obtain L-glutamic acid.

Brief Description of the Drawings

- Fig. 1 shows the construction procedure of pBR-sucAB,
 Fig. 2 shows a procedure for disrupting the *sucA* gene on the chromosomal DNA of *Escherichia coli* W3110,
 and
 Fig. 3 shows the construction procedure of pGK.

Examples

The present invention is further described by the following examples.

Example 1

(1) Cloning of *sucA* gene and dihydrolipoamide succinyl transferase gene of *Escherichia coli*

The nucleotide sequences of *sucA* gene and dihydrolipoamide succinyl transferase gene (hereinafter referred to as *sucB* gene) of *Escherichia coli* K12 are known. The known nucleotide sequences of *sucA* gene and *sucB* gene are disclosed in Euro. J. Biochem., Vol. 141, pp. 351 to 374 (1984), and also shown here as Sequ ID No. 7 in the sequence listing. The nucleotide sequence from the 327th through the 3128th base residues corresponds to ORF (open reading frame) of the *sucA* gene, while that from the 3143rd through the 4357th base residues corresponds to ORF of the *sucB* gene. According to the nucleotide sequences reported, primers shown in Sequ ID No.1 to 4 were synthesized and *sucA* and *sucB* genes were amplified by PCR method employing the chromosomal DNA of *Escherichia coli* W3110 as a template.

The synthetic primers used to amplify the *sucA* gene had the nucleotide sequences shown in Sequ ID No.1 and 2, and Sequ ID No.1 corresponds to the sequence consisting of the 45th through the 65th base residues in the nucleotide sequence figure of the *sucA* gene described in Euro. J. Biochem., Vol. 141, p. 354 (1984). It also corresponds to the sequence consisting of the 45th through the 65th base residues of the nucleotide sequence shown as Sequ ID No. 7.

Sequ ID No. 2 corresponds to the sequence consisting of the 3173rd through the 3193rd base residues in the nucleotide sequence figure of the *sucB* gene shown in Euro. J. Biochem., Vol. 141, p. 364 (1984). It also corresponds to the sequence consisting of the 3173rd through the 3193rd base residues of the nucleotide sequence shown as Sequ ID No. 7.

The synthetic primers used to amplify the *sucB* gene had the nucleotide sequences shown in Sequ ID No.3 and 4, and Sequ ID No. 3 corresponds to the sequence consisting of the 2179th through 2198th base residues in the nucleotide sequence figure of the *sucA* gene shown in Euro. J. Biochem., Vol. 141, p. 354 (1984). It also corresponds to the sequence consisting of the 2179th through the 2198th base residues of the nucleotide sequence shown as Sequ No. 7.

Sequ ID No. 4 corresponds to the sequence consisting of the 4566th through the 4591st base residues in the nucleotide sequence figure of the *sucB* gene shown in Euro. J. Biochem., Vol. 141, p. 364 (1984). It also corresponds to the sequence consisting of the 4566th through the 4591st base residues of the nucleotide sequence shown as Sequ ID No. 7. The *sucA* gene and the *sucB* gene form an operon.

The chromosomal DNA of *Escherichia coli* W3110 was recovered by a standard method (Seibutsukogaku Jikkensho, Ed. by Nippon Seibutsu Kogaku Kai, pp. 97 to 98, Baifukan (1992)).

The PCR reaction was carried out under the standard conditions described on page 8 of PCR Technology (Ed. by Henry Erlich, Stockton Press (1989)).

Both ends of PCR products thus produced were converted into blunt ends using T4 DNA polymerase and cloned into a vector pBR322 at the *EcoRV* site. The plasmid obtained by cloning the *sucA* gene into pBR322 was designated as pBR-sucA, and that constructed with *sucB* was designated as pBR-sucB. The plasmids

thus obtained were introduced into *Escherichia coli* JM109 and the plasmids were prepared. Then the restriction maps were constructed and compared with the restriction maps of the sucA and sucB genes reported, thereby confirming that the genes which had been cloned were the sucA and sucB genes.

As shown in Fig. 1, pBR-sucB was digested with KpnI and EcoRI to prepare a DNA fragment containing the sucB gene. pBR-sucA was digested with KpnI and EcoRI to prepare a large fragment. Both fragments were ligated using T4 DNA ligase to produce pBR-sucAB.

(2) Disruption of the sucA gene on chromosomal DNA of *Escherichia coli* W3110

Fig. 2 outlines the disruption of the sucA gene on the chromosomal DNA of *Escherichia coli* W3110.

pBR-sucAB was digested with KpnI and T4 DNA polymerase was used to obtain blunt ends. On the other hand, pUC4K (purchased from Pharmacia) was digested with PstI to prepare a DNA fragment containing a kanamycin-resistance gene, which was converted to have blunt ends using T4 DNA polymerase. Both fragments were ligated using T4 DNA ligase to obtain pBR-sucA::Km^r. From this plasmid, a HindIII-EcoRI fragment containing the kanamycin-resistance gene was cut out as a linear DNA, which was used to transform *Escherichia coli* JC7623 (thr-1, ara-14, leuB6, Δ(gpt-proA)62, lacY1, tsx-23, supE44, gal1K2, λ⁻, rac⁻, sbcB15, hisG4, rfdD1, recB21, recC22, rpsL31, kdgK51, xyl-5, mtl-1, argE3, thi-1) obtained from the *Escherichia coli* Genetic Stock Center (at Yale University, USA), and strains in which the sucA gene on the chromosomal DNA was replaced with the sucA gene into which the kanamycin-resistance gene had been inserted (sucA::Km^r) were screened on L medium (bactotrypton 10 g/l, yeast extract 5 g/l, NaCl 5 g/l, agar 15 g/l, pH 7.2) supplemented with 25 μg/ml of kanamycin. Since *Escherichia coli* JC7623 possessed recB⁻, recC⁻ and sbcB⁻, recombination can be achieved at a high frequency even if the transformation is conducted using a linear DNA.

From each of twelve (12) kanamycin-resistant strains thus obtained, the chromosomal DNA was prepared and digested with KpnI. By southern hybridization using a DNA fragment containing the sucA gene as a probe, all of 12 strains were confirmed to be strains in which the sucA gene on the chromosomal DNA was replaced with the sucA gene into which kanamycin-resistance gene had been inserted. While a wild strain exhibits two bands at 5.2 Kb and 6.2 Kb due to the presence of KpnI site in the DNA fragment containing the sucA gene when a 2.6 Kb EcoRI-HindIII fragment containing the sucA gene of pBR-sucA was used as the probe in the southern hybridization, strains having the replacement with sucA gene into which kanamycin-resistance gene has been inserted exhibits only one band at 11.4 Kb due to the disruption of the KpnI site upon introduction of the kanamycin-resistance gene. The kanamycin-resistance *Escherichia coli* JC7623 (sucA::Km^r) thus obtained was then infected with P1 phage and the phage lysate was prepared. Then *Escherichia coli* W3100 strain was transduced with the sucA::Km^r. Transduction with P1 phage was conducted by a standard method (Seibutsu-kogaku Jikkensho, Ed. by Nippon Seibutsu Kogaku Kai, pp. 75 to 76, Baifukan (1992)). The representative of the kanamycin-resistance strains isolated was designated as W3110 sucA::Km^r.

The α-KGDH activities of the strain W3110 sucA::Km^r and *Escherichia coli* W3110 were determined according to the method by Reed et al (Methods in Enzymology, Vol. 13, pp. 55 (1969)). The results are shown in Table 1. α-KGDH activity of *Escherichia coli* W3110 sucA::Km^r was not detected. Thus, *Escherichia coli* W3110 sucA::Km^r is a strain deficient in α-KGDH activity.

Table 1

	W3110	W3110sucA::Km ^r
α-KGDH activity	3.70	Not detected
(Unit : micromoles/mg protein/min)		

(3) Cloning of gdhA gene of *Escherichia coli* W3110

Similarly as in the cloning of the sucA and sucB genes, the PCR method was used to clone the gdhA gene. According to the nucleotide sequence of gdhA gene reported by Fernando et al, primers for PCR were synthesized. The nucleotide sequence of the gdhA gene is disclosed in Gene, Vol. 27, pp.193 to 199 (1984), and is also shown here as Sequ ID No. 8 in the sequence listings. The nucleotide sequences of the primers are shown in Sequ ID Nos. 5 and 6.

Sequ ID No. 5 corresponds to the sequence from the 191st through the 171st base residues in the nucleotide sequence figure of gdhA gene shown in Gene, Vol. 27, p.195 (1984), and it also corresponds to the

sequence from the 3rd through the 23rd base residues in Sequ ID No. 8.

Sequ ID No. 6 corresponds to the sequence consisting of the 1687th through the 1707th base residues in the nucleotide sequence figure of the gdhA gene shown in Gene, Vol. 27, p.195, (1984), and it also corresponds to the sequence consisting of 1880th through the 1900th base residues in Sequ ID No. 8.

Using the synthetic primers the gdhA gene was amplified by the PCR method employing the chromosomal DNA of Escherichia coli W3110 as a template. PCR products thus obtained were purified and converted to have blunt ends using T4 DNA polymerase, and then ligated to pBR 322 digested with EcoRV to obtain a plasmid pBRGDH.

(4) Construction of a plasmid having the ppc and gdhA genes

Fig. 3 shows the procedure for the construction of a plasmid having the ppc and gdhA genes. The plasmid pS2 in which 4.4Kb Sall fragment containing the whole region of the ppc gene derived from Escherichia coli K-12 was inserted into the Sall site of pBR322 (J. Biochem, Vol. 9, pp.909 to 916 (1984)) was digested with HindIII and both ends were made blunt using T4 DNA polymerase. On the other hand, a DNA fragment containing the gdhA gene synthesized by the PCR method was converted to have blunt ends using T4 DNA polymerase. Subsequently, both fragments were ligated using T4 DNA ligase. The plasmid thus obtained was used to transform a GDH deficient strain, Escherichia coli PA 340 (thr-1, fhuA2, leuB6, lacY1, supE44, gal-6, λ -, gdh-1, hisG1, rfaD1, galP63, Δ (glbB-F), rpsL19, malT1(lambdaR), xy1-7, mtl-2, argH1, thi-1) obtained from the Escherichia coli Genetic Stock Center (at Yale University, USA) and an ampicillin-resistant strain which had lost its glutamic acid requirement for growth was isolated. From this strain, a plasmid was prepared and the restriction map was constructed, whereby it was confirmed that the ppc and gdhA genes were present on this plasmid. This plasmid was designated as pGK.

(5) Introduction of pS2, pBRGDH and pGK into α -KGDH deficient strain Escherichia coli W3100 sucA::Km^r and evaluation of L-glutamic acid-production

The α -KGDH-deficient strain, Escherichia coli W3100 sucA::Km^r was transformed with each of pS2, pBRGDH and pGK, and each of the transformed strains was inoculated into a 500-ml shaker flask containing 20 ml of the culture medium having the composition shown in Table 2. Cultivation was then carried out at 37 °C until the glucose in the culture medium was consumed completely. The results are shown in Table 3.

Table 2

Component	Concentration (g/l)
Glucose	40
(NH ₄) ₂ SO ₄	20
KH ₂ PO ₄	1
MgSO ₄ ·7H ₂ O	1
FeSO ₄ ·7H ₂ O	0.01
MnSO ₄ ·5H ₂ O	0.01
Yeast extract	2
Thiamine hydrochloride	0.01
CaCO ₃	50

Table 3

Strain	Accumulated L-glutamic acid (g/l)
W3110 <i>sucA::Km^r</i>	19.2
W3110 <i>sucA::Km^r/pS2</i>	19.9
W3110 <i>sucA::Km^r/pBRGDH</i>	2.8
W3110 <i>sucA::Km^r/pGK (AJ 12949)</i>	23.3

Although the transformed strain having the PPC activity amplified by the introduction of pS2 exhibited slightly reduced growth as compared with the host strain, W3110 *sucA::Km^r*, it accumulated L-glutamic acid in an amount similar to that accumulated by the host strain. The strain having GDH activity amplified by the introduction of pBRGDH exhibited quite poor growth, and the amount of the accumulated L-glutamic acid was surprisingly smaller than that accumulated by the strain W3110 *sucA::Km^r*.

On the contrary, the transformed strain in which both of PPC and GDH activities were amplified simultaneously by the introduction of pGK exhibited growth similar to that of the host strain while producing an increased amount of accumulated L-glutamic acid. *Escherichia coli* W3110 *sucA::Km^r* into which pGK plasmid having the *ppc* and *gdhA* genes had been introduced was designated as AJ 12949. *Escherichia coli* AJ 12949 was originally deposited under the accession number FERM P-14039 on December 28, 1993, at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken 305, Japan, and the deposit was converted into a deposit under the Budapest Treaty under the accession number FERM BP-4881 on November 11, 1994.

The host strain, namely, W3110 *sucA::Km^r* can be obtained by curing the plasmid from the deposited strain, AJ 12949 without damaging the cell. The plasmid may be lost from AJ 12949 spontaneously, or may be cured in a curing procedure (Bact. Rev., Vol. 36, p.361 to 405 (1972)). An example of the curing procedure is as follows. The strain AJ 12949 is inoculated to the L-broth medium (Bactotrypton 10 g/l, yeast extract 5 g/l, NaCl 5 g/l, pH 7.2), and cultivated at 40°C overnight. The culture broth is diluted appropriately, and spread onto the L-medium. After incubating it at 37°C overnight, the colonies formed are transferred to the L-medium containing 100 µg/ml of ampicillin and then ampicillin-sensitive colonies are isolated. The strain thus obtained is W3110 *sucA::Km^r*.

Advantages of the Invention

The method according to the present invention provides a mutant of the genus *Escherichia* having a higher productivity of L-glutamic acid as well as the efficient and low-cost method for the production of L-glutamic acid.

SEQUENCE LISTING

5

GENERAL INFORMATION:

APPLICANT:

10 NAME: Ajinomoto Co., Inc.
STREET: 15-1, Kyobashi 1-chome
CITY: Chuo-ku, Tokyo
COUNTRY: Japan
POSTAL CODE: none

15 TITLE OF INVENTION: Method of producing L-glutamic acid by fermentation

NUMER OF SEQUENCES: 8

COMPUTER READABLE FORM:

20 MEDIUM TYPE: Diskette
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS-DOS

25

SEQUENCE DESCRIPTION:

30 SEQ ID No.: 1
Length : 21 base pairs
Type : Nucleotide
Strandedness : Single
Topology : Linear
Molecule type: Synthetic DNA
Feature : Primer for amplification of sucA gene of Escherichia coli
Sequence
35 ACGCGCAAGC GTCGCATCAG G 21

40 SEQ ID No.: 2
Length : 21 base pairs
Type : Nucleotide
Strandedness : Single
Topology : Linear
Molecule type: Synthetic DNA
Feature : Primer for amplification of sucA gene of Escherichia coli
45 Sequence
ATCGGCTACG AATTCAGGCA G 21

50 SEQ ID No.: 3
Length : 20 base pairs
Type : Nucleotide
Strandedness : Single
Topology : Linear
55 Molecule type: Synthetic DNA
Feature : Primer for amplification of sucB gene of Escherichia coli

EP 0 670 370 A2

Sequence

CCGGTCGCGG TACCTTCTTC

20

SEQ ID No.: 4

Length : 26 base pairs

Type : Nucleotide

Strandedness : Single

Topology : Linear

Molecule type: Synthetic DNA

Feature : Primer for amplification of sucB gene of Escherichia coli

Sequence

CGTAGACCGA ATTCTTCGTA TCGCTT

26

SQ ID No.: 5

Length : 21 base pairs

Type : Nucleotide

Strandedness : Single

Topology : Linear

Molecule type: Synthetic DNA

Feature : Primer for amplification of gdhA gene of Escherichia coli

Sequence

GGGTGGCAAA GCTTTAGCGT C

21

SEQ ID No.: 6

Length : 21 base pairs

Type : Nucleotide

Strandedness : Single

Topology : Linear

Molecule type: Synthetic DNA

Feature : Primer for amplification of gdhA gene of Escherichia coli

Sequence

TCGAGAAGCA TGCATTATAT A

21

SEQ ID No.: 7

Length : 4623 base pairs

Type : Nucleotide

Strandedness : Single

Topology : Linear

Molecule type: Genomic DNA

Original source

Organism : Escherichia coli

Features

Feature key : CDS

=>from 327 to 318 bp coding sequence

Location : 327..3128

Method of feature determination : E

Feature key : CDS

=>from 3143 to 4357 bp coding sequence

Location : 3143..4357

Method of feature determination : E

EP 0 670 370 A2

Sequence

[illegible]

EP 0 670 370 A2

			285				290				295						
5	CAC	ATG	GGC	TTC	TCG	TCT	GAC	TTC	CAG	ACC	GAT	GGC	GGC	CTG	GTG	CAC	1265
	His	Met	Gly	Phe	Ser	Ser	Asp	Phe	Gln	Thr	Asp	Gly	Gly	Leu	Val	His	
			300						305					310			
	CTG	GCG	CTG	GCG	TTT	AAC	CCG	TCT	CAC	CTT	GAG	ATT	GTA	AGC	CCG	GTA	1313
	Leu	Ala	Leu	Ala	Phe	Asn	Pro	Ser	His	Leu	Glu	Ile	Val	Ser	Pro	Val	
			315				320							325			
10	GTT	ATC	GGT	TCT	GTT	CGT	GCC	CGT	CTG	GAC	AGA	CTT	GAT	GAG	CCG	AGC	1361
	Val	Ile	Gly	Ser	Val	Arg	Ala	Arg	Leu	Asp	Arg	Leu	Asp	Glu	Pro	Ser	
			330				335							340		345	
	AGC	AAC	AAA	GTG	CTG	CCA	ATC	ACC	ATC	CAC	GGT	GAC	GCC	GCA	GTG	ACC	1409
	Ser	Asn	Lys	Val	Leu	Pro	Ile	Thr	Ile	His	Gly	Asp	Ala	Ala	Val	Thr	
						350										360	
15	GGG	CAG	GGC	GTG	GTT	CAG	GAA	ACC	CTG	AAC	ATG	TCG	AAA	GCG	CGT	GGT	1457
	Gly	Gln	Gly	Val	Val	Gln	Glu	Thr	Leu	Asn	Met	Ser	Lys	Ala	Arg	Gly	
						365										375	
	TAT	GAA	GTT	GGC	GGT	ACG	GTA	CGT	ATC	GTT	ATC	AAC	AAC	CAG	GTT	GGT	1505
	Tyr	Glu	Val	Gly	Gly	Thr	Val	Arg	Ile	Val	Ile	Asn	Asn	Gln	Val	Gly	
						380										390	
20	TTC	ACC	ACC	TCT	AAT	CCG	CTG	GAT	GCC	CGT	TCT	ACG	CCG	TAC	TGT	ACT	1553
	Phe	Thr	Thr	Ser	Asn	Pro	Leu	Asp	Ala	Arg	Ser	Thr	Pro	Tyr	Cys	Thr	
							400									405	
	GAT	ATC	GGT	AAG	ATG	GTT	CAG	GCC	CCG	ATT	TTC	CAC	GTT	AAC	GCG	GAC	1601
	Asp	Ile	Gly	Lys	Met	Val	Gln	Ala	Pro	Ile	Phe	His	Val	Asn	Ala	Asp	
						415										425	
25	GAT	CCG	GAA	GCC	GTT	GCC	TTT	GTG	ACC	CGT	CTG	GCG	CTC	GAT	TTC	CGT	1649
	Asp	Pro	Glu	Ala	Val	Ala	Phe	Val	Thr	Arg	Leu	Ala	Leu	Asp	Phe	Arg	
						430										440	
	AAC	ACC	TTT	AAA	CGT	GAT	GTC	TTC	ATC	GAC	CTG	GTG	TCG	TAC	CGC	CGT	1697
	Asn	Thr	Phe	Lys	Arg	Asp	Val	Phe	Ile	Asp	Leu	Val	Ser	Tyr	Arg	Arg	
						445										455	
30	CAC	GGC	CAC	AAC	GAA	GCC	GAC	GAG	CCG	AGC	GCA	ACC	CAG	CCG	CTG	ATG	1745
	His	Gly	His	Asn	Glu	Ala	Asp	Glu	Pro	Ser	Ala	Thr	Gln	Pro	Leu	Met	
							460									470	
	TAT	CAG	AAA	ATC	AAA	AAA	CAT	CCG	ACA	CCG	CGC	AAA	ATC	TAC	GCT	GAC	1793
	Tyr	Gln	Lys	Ile	Lys	Lys	His	Pro	Thr	Pro	Arg	Lys	Ile	Tyr	Ala	Asp	
							480									485	
35	AAG	CTG	GAG	CAG	GAA	AAA	GTG	GCG	ACG	CTG	GAA	GAT	GCC	ACC	GAG	ATG	1841
	Lys	Leu	Glu	Gln	Glu	Lys	Val	Ala	Thr	Leu	Glu	Asp	Ala	Thr	Glu	Met	
							495									505	
	GTT	AAC	CTG	TAC	CGC	GAT	GCG	CTG	GAT	GCT	GGC	GAT	TGC	GTA	GTG	GCA	1889
	Val	Asn	Leu	Tyr	Arg	Asp	Ala	Leu	Asp	Ala	Gly	Asp	Cys	Val	Val	Ala	
						510										520	
40	GAG	TGG	CGT	CCG	ATG	AAC	ATG	CAC	TCT	TTC	ACC	TGG	TCG	CCG	TAC	CTC	1937
	Glu	Trp	Arg	Pro	Met	Asn	Met	His	Ser	Phe	Thr	Trp	Ser	Pro	Tyr	Leu	
							525									535	
	AAC	CAC	GAA	TGG	GAC	GAA	GAG	TAC	CCG	AAC	AAA	GTT	GAG	ATG	AAG	CGC	1985
	Asn	His	Glu	Trp	Asp	Glu	Glu	Tyr	Pro	Asn	Lys	Val	Glu	Met	Lys	Arg	
							540									550	
45	CTG	CAG	GAG	CTG	GCG	AAA	CGC	ATC	AGC	ACG	GTG	CCG	GAA	GCA	GTT	GAA	2033
	Leu	Gln	Glu	Leu	Ala	Lys	Arg	Ile	Ser	Thr	Val	Pro	Glu	Ala	Val	Glu	
							560									565	
	ATG	CAG	TCT	CGC	GTT	GCC	AAG	ATT	TAT	GGC	GAT	CGC	CAG	GCG	ATG	GCT	2081
	Met	Gln	Ser	Arg	Val	Ala	Lys	Ile	Tyr	Gly	Asp	Arg	Gln	Ala	Met	Ala	
							575									585	
50	GCC	GGT	GAG	AAA	CTG	TTC	GAC	TGG	GGC	GGT	GCG	GAA	AAC	CTC	GCT	TAC	2129
	Ala	Gly	Glu	Lys	Leu	Phe	Asp	Trp	Gly	Gly	Ala	Glu	Asn	Leu	Ala	Tyr	
							590									600	
	GCC	ACG	CTG	GTT	GAT	GAA	GGC	ATT	CCG	GTT	CGC	CTG	TCG	GGT	GAA	GAC	2177
	Ala	Thr	Leu	Val	Asp	Glu	Gly	Ile	Pro	Val	Arg	Leu	Ser	Gly	Glu	Asp	
							605									615	
55	TCC	GGT	CGC	GGT	ACC	TTC	TTC	CAC	CGC	CAC	GCG	GTG	ATC	CAC	AAC	CAG	2225

EP 0 670 370 A2

5	Ser Gly Arg Gly Thr Phe Phe His Arg His Ala Val Ile His Asn Gln	
	620 625 630	
	TCT AAC GGT TCC ACT TAC ACG CCG CTG CAA CAT ATC CAT AAC GGG CAG	2273
	Ser Asn Gly Ser Thr Tyr Thr Pro Leu Gln His Ile His Asn Gly Gln	
	635 640 645	
10	GGC GCG TTC CGT GTC TGG GAC TCC GTA CTG TCT GAA GAA GCA GTG CTG	2321
	Gly Ala Phe Arg Val Trp Asp Ser Val Leu Ser Glu Glu Ala Val Leu	
	650 655 660	
	GCG TTT GAA TAT GGT TAT GCC ACC GCA GAA CCA CGC ACT CTG ACC ATC	2369
	Ala Phe Glu Tyr Gly Tyr Ala Thr Ala Glu Pro Arg Thr Leu Thr Ile	
	670 675 680	
	TGG GAA GCG CAG TTC GGT GAC TTC GCC AAC GGT GCG CAG GTG GTT ATC	2417
	Trp Glu Ala Gln Phe Gly Asp Phe Ala Asn Gly Ala Gln Val Val Ile	
	685 690 695	
15	GAC CAG TTC ATC TCC TCT GGC GAA CAG AAA TGG GGC CGG ATG TGT GGT	2465
	Asp Gln Phe Ile Ser Ser Gly Glu Gln Lys Trp Gly Arg Met Cys Gly	
	700 705 710	
	CTG GTG ATG TTG CTG CCG CAC GGT TAC GAA GGG CAG GGG CCG GAG CAC	2513
	Leu Val Met Leu Leu Pro His Gly Tyr Glu Gly Gln Gly Pro Glu His	
	715 720 725	
20	TCC TCC GCG CGT CTG GAA CGT TAT CTG CAA CTT TGT GCT GAG CAA AAC	2561
	Ser Ser Ala Arg Leu Glu Arg Tyr Leu Gln Cys Ala Glu Gln Asn	
	730 735 740 745	
	ATG CAG GTT TGC GTA CCG TCT ACC CCG GCA CAG GTT TAC CAC ATG CTG	2609
	Met Gln Val Cys Val Pro Ser Thr Pro Ala Gln Val Tyr His Met Leu	
	750 755 760	
25	CGT CGT CAG GCG CTG CCG GGG ATG CGT CGT CCG CTG GTC GTG ATG TCG	2657
	Arg Arg Gln Ala Leu Arg Gly Met Arg Arg Pro Leu Val Val Met Ser	
	765 770 775	
	CCG AAA TCC CTG CTG CGT CAT CCG CTG GCG GTT TCC AGC CTC GAA GAA	2705
	Pro Lys Ser Leu Leu Arg His Pro Leu Ala Val Ser Ser Leu Glu Glu	
	780 785 790	
30	CTG GCG AAC GGC ACC TTC CTG CCA GCC ATC GGT GAA ATC GAC GAG CTT	2753
	Leu Ala Asn Gly Thr Phe Leu Pro Ala Ile Gly Glu Ile Asp Glu Leu	
	795 800 805	
	GAT CCG AAG GGC GTG AAG CGC GTA GTG ATG TGT TCT GGT AAG GTT TAT	2801
	Asp Pro Lys Gly Val Lys Arg Val Val Met Cys Ser Gly Lys Val Tyr	
	810 815 820 825	
35	TAC GAC CTG CTG GAA CAG CGT CGT AAG AAC AAT CAA CAC GAT GTC GCC	2849
	Tyr Asp Leu Leu Glu Gln Arg Arg Lys Asn Asn Gln His Asp Val Ala	
	830 835 840	
	ATT GTG CGT ATC GAG CAA CTC TAC CCG TTC CCG CAT AAA GCG ATG CAG	2897
	Ile Val Arg Ile Glu Gln Leu Tyr Pro Phe Pro His Lys Ala Met Gln	
	845 850 855	
40	GAA GTG TTG CAG CAG TTT GCT CAC GTC AAG GAT TTT GTC TGG TGC CAG	2945
	Glu Val Leu Gln Gln Phe Ala His Val Lys Asp Phe Val Trp Cys Gln	
	860 865 870	
	GAA GAG CCG CTC AAC CAG GGC GCA TGG TAC TGC AGC CAG CAT CAT TTC	2993
	Glu Glu Pro Leu Asn Gln Gly Ala Trp Tyr Cys Ser Gln His His Phe	
	875 880 885	
45	CGT GAA GTG ATT CCG TTT GGG GCT TCT CTG CGT TAT GCA GGC CGC CCG	3041
	Arg Glu Val Ile Pro Phe Gly Ala Ser Leu Arg Tyr Ala Gly Arg Pro	
	890 895 900 905	
	GCC TCC GCC TCT CCG GCG GTA GGG TAT ATG TCC GTT CAC CAG AAA CAG	3089
	Ala Ser Ala Ser Pro Ala Val Gly Tyr Met Ser Val His Gln Lys Gln	
	910 915 920	
50	CAA CAA GAT CTG GTT AAT GAC GCG CTG AAC GTC GAA TAAATAAAGG	3135
	Gln Gln Asp Leu Val Asn Asp Ala Leu Asn Val Glu	
	925 930	
	ATACACA ATG AGT AGC GTA GAT ATT CTG GTC CCT GAC CTG CCT GAA TCC	3184
	Met Ser Ser Val Asp Ile Leu Val Pro Asp Leu Pro Glu Ser	
55	1 5 10	

EP 0 670 370 A2

5	GTA	GCC	GAT	GCC	ACC	GTC	GCA	ACC	TGG	CAT	AAA	AAA	CCC	GGC	GAC	GCA	3232
	Val	Ala	Asp	Ala	Thr	Val	Ala	Thr	Trp	His	Lys	Lys	Pro	Gly	Asp	Ala	
	15					20					25					30	
	GTC	GTA	CGT	GAT	GAA	GTG	CTG	GTA	GAA	ATC	GAA	ACT	GAC	AAA	GTG	GTA	3280
	Val	Val	Arg	Asp	Glu	Val	Leu	Val	Glu	Ile	Glu	Thr	Asp	Lys	Val	Val	
					35					40					45		
10	CTG	GAA	GTA	CCG	GCA	TCA	GCA	GAC	GGC	ATT	CTG	GAT	GCG	GTT	CTG	GAA	3328
	Leu	Glu	Val	Pro	Ala	Ser	Ala	Asp	Gly	Ile	Leu	Asp	Ala	Val	Leu	Glu	
				50					55					60			
	GAT	GAA	GGT	ACA	ACG	GTA	ACG	TCT	CGT	CAG	ATC	CTT	GGT	GCG	CTG	CGT	3376
	Asp	Glu	Gly	Thr	Thr	Val	Thr	Ser	Arg	Gln	Ile	Leu	Gly	Arg	Leu	Arg	
				65				70					75				
15	GAA	GGC	AAC	AGC	GCC	GGT	AAA	GAA	ACC	AGC	GCC	AAA	TCT	GAA	GAG	AAA	3424
	Glu	Gly	Asn	Ser	Ala	Gly	Lys	Glu	Thr	Ser	Ala	Lys	Ser	Glu	Glu	Lys	
		80					85					90					
	GCG	TCC	ACT	CCG	GCG	CAA	CGC	CAG	CAG	GCG	TCT	CTG	GAA	GAG	CAA	AAC	3472
	Ala	Ser	Thr	Pro	Ala	Gln	Arg	Gln	Gln	Ala	Ser	Leu	Glu	Glu	Gln	Asn	
		95				100					105				110		
20	AAC	GAT	GCG	TTA	AGC	CCG	GCG	ATC	CGT	CGC	CTG	CTG	GCT	GAA	CAC	AAT	3520
	Asn	Asp	Ala	Leu	Ser	Pro	Ala	Ile	Arg	Arg	Leu	Leu	Ala	Glu	His	Asn	
					115				120						125		
	CTC	GAC	GCC	AGC	GCC	ATT	AAA	GGC	ACC	GGT	GTG	GGT	GGT	CGT	CTG	ACT	3568
	Leu	Asp	Ala	Ser	Ala	Ile	Lys	Gly	Thr	Gly	Val	Gly	Gly	Arg	Leu	Thr	
				130				135						140			
25	CGT	GAA	GAT	GTG	GAA	AAA	CAT	CTG	GCG	AAA	GCC	CCG	GCG	AAA	GAG	TCT	3616
	Arg	Glu	Asp	Val	Glu	Lys	His	Leu	Ala	Lys	Ala	Pro	Ala	Lys	Glu	Ser	
			145				150						155				
	GCT	CCG	GCA	GCG	GCT	GCT	CCG	GCG	GCG	CAA	CCG	GCT	CTG	GCT	GCA	CGT	3664
	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Ala	Gln	Pro	Ala	Leu	Ala	Ala	Arg	
		160					165					170					
30	AGT	GAA	AAA	CGT	GTC	CCG	ATG	ACT	CGC	CTG	CGT	AAG	CGT	GTG	GCA	GAG	3712
	Ser	Glu	Lys	Arg	Val	Pro	Met	Thr	Arg	Leu	Arg	Lys	Arg	Val	Ala	Glu	
		175				180					185				190		
	CGT	CTG	CTG	GAA	GCG	AAA	AAC	TCC	ACC	GCC	ATG	CTG	ACC	ACG	TTC	AAC	3760
	Arg	Leu	Leu	Glu	Ala	Lys	Asn	Ser	Thr	Ala	Met	Leu	Thr	Thr	Phe	Asn	
				195						200					205		
35	GAA	GTC	AAC	ATG	AAG	CCG	ATT	ATG	GAT	CTG	CGT	AAG	CAG	TAC	GGT	GAA	3808
	Glu	Val	Asn	Met	Lys	Pro	Ile	Met	Asp	Leu	Arg	Lys	Gln	Tyr	Gly	Glu	
			210						215					220			
	GCG	TTT	GAA	AAA	CGC	CAC	GGC	ATC	CGT	CTG	GGC	TTT	ATG	TCC	TTC	TAC	3856
	Ala	Phe	Glu	Lys	Arg	His	Gly	Ile	Arg	Leu	Gly	Phe	Met	Ser	Phe	Tyr	
		225					230						235				
40	GTG	AAA	GCG	GTG	GTT	GAA	GCC	CTG	AAA	CGT	TAC	CCG	GAA	GTG	AAC	GCT	3904
	Val	Lys	Ala	Val	Val	Glu	Ala	Leu	Lys	Arg	Tyr	Pro	Glu	Val	Asn	Ala	
		240					245					250					
	TCT	ATC	GAC	GGC	GAT	GAC	GTG	GTT	TAC	CAC	AAC	TAT	TTC	GAC	GTC	AGC	3952
	Ser	Ile	Asp	Gly	Asp	Asp	Val	Val	Tyr	His	Asn	Tyr	Phe	Asp	Val	Ser	
		255			260						265				270		
45	ATG	GCG	GTT	TCT	ACG	CCG	GCG	GGC	CTG	GTG	ACG	CCG	GTT	CTG	CGT	GAT	4000
	Met	Ala	Val	Ser	Thr	Pro	Arg	Gly	Leu	Val	Thr	Pro	Val	Leu	Arg	Asp	
				275					280					285			
	GTC	GAT	ACC	CTC	GGC	ATG	GCA	GAC	ATC	GAG	AAG	AAA	ATC	AAA	GAG	CTG	4048
	Val	Asp	Thr	Leu	Gly	Met	Ala	Asp	Ile	Glu	Lys	Lys	Ile	Lys	Glu	Leu	
			290						295				300				
50	GCA	GTC	AAA	GGC	CGT	GAC	GGC	AAG	CTG	ACC	GTT	GAA	GAT	CTG	ACC	GGT	4096
	Ala	Val	Lys	Gly	Arg	Asp	Gly	Lys	Leu	Thr	Val	Glu	Asp	Leu	Thr	Gly	
			305				310						315				
	GGT	AAC	TTC	ACC	ATC	ACC	AAC	GGT	GGT	GTG	TTC	GGT	TCC	CTG	ATG	TCT	4144
	Gly	Asn	Phe	Thr	Ile	Thr	Asn	Gly	Gly	Val	Phe	Gly	Ser	Leu	Met	Ser	
		320					325					330					
55	ACG	CCG	ATC	ATC	AAC	CCG	CCG	CAG	AGC	GCA	ATT	CTG	GGT	ATG	CAC	GCT	4192
	Thr	Pro	Ile	Ile	Asn	Pro	Pro	Gln	Ser	Ala	Ile	Leu	Gly	Met	His	Ala	

EP 0 670 370 A2

```

5      335      340      345      350
ATC AAA GAT CGT CCG ATG GCG GTG AAT GGT CAG GTT GAG ATC CTG CCG 4240
Ile Lys Asp Arg Pro Met Ala Val Asn Gly Gln Val Glu Ile Leu Pro
      355      360      365
ATG ATG TAC CTG GCG CTG TCC TAC GAT CAC CGT CTG ATC GAT GGT CGC 4288
Met Met Tyr Leu Ala Leu Ser Tyr Asp His Arg Leu Ile Asp Gly Arg
      370      375      380
10     GAA TCC GTG GGC TTC CTG GTA ACG ATC AAA GAG TTG CTG GAA GAT CCG 4336
Glu Ser Val Gly Phe Leu Val Thr Ile Lys Glu Leu Leu Glu Asp Pro
      385      390      395
ACG CGT CTG CTG CTG GAC GTG TAGTAGTTTA AGTTTCACCT GCACTGTAGA 4387
Thr Arg Leu Leu Leu Asp Val
      400      405
15     CCGGATAAGG CATTATCGCC TTCTCCGGCA ATTGAAGCCT GATGCGACGC TGACGCGTCT 4447
TATCAGGCCCT ACGGGACCAC CAATGTAGGT CGGATAAGGC GCAACGCCGC ATCCGACAAG 4507
CGATGCCCTGA TGTGACGTTT AACGTGTCTT ATCAGGCCTA CGGGTGACCG ACAATGCCCG 4567
GAAGCGATAC GAAATATTCTG GTCTACGGTT TAAAAGATAA CGATTACTGA AGGATG 4623

```

```

20     SEQ ID No.: 8
      Length : 1937 base pairs
      Type : Nucleotide
      Strandedness : Single
      Topology : Linear
25     Molecule type: Genomic DNA
      Original source
      Organism : Escherichia coli
      Sequence feature
      Feature key : CDS           =>from 194 to 1537 bp coding sequence
      Location : 194..1537
30     Method of feature determination : E

```

```

Sequence
CCGGGTGGCA AAACCTTTAGC GTCTGAGGTT ATCGCAATTT GGTATGAGA TTACTCTCGT 60
TATTAATTTG CTTTCCTGGG TCATTTTTTT CTTGCTTACC GTCACATTCT TGATGGTATA 120
GTCGAAAACG GCAAAAGCAC ATGACATAAA CAACATAAGC ACAATCGTAT TAATATATAA 180
GGGTTTTATA TCT ATG GAT CAG ACA TAT TCT CTG GAG TCA TTC CTC AAC 229
35     Met Asp Gln Thr Tyr Ser Leu Glu Ser Phe Leu Asn
      1      5      10
CAT GTC CAA AAG CGC GAC CCG AAT CAA ACC GAG TTC GCG CAA GCC GTT 277
His Val Gln Lys Arg Asp Pro Asn Gln Thr Glu Phe Ala Gln Ala Val
      15      20      25
CGT GAA GTA ATG ACC ACA CTC TGG CCT TTT CTT GAA CAA AAT CCA AAA 325
Arg Glu Val Met Thr Thr Leu Trp Pro Phe Leu Glu Gln Asn Pro Lys
40     30      35      40
TAT CGC CAG ATG TCA TTA CTG GAG CGT CTG GTT GAA CCG GAG CGC GTG 373
Tyr Arg Gln Met Ser Leu Leu Glu Arg Leu Val Glu Pro Glu Arg Val
      45      50      55      60
ATC CAG TTT CGC GTG GTA TGG GTT GAT GAT CGC AAC CAG ATA CAG GTC 421
Ile Gln Phe Arg Val Val Trp Val Asp Asp Arg Asn Gln Ile Gln Val
45     65      70      75
AAC CGT GCA TGG CGT GTG CAG TTC AGC TCT GCC ATC GGC CCG TAC AAA 469
Asn Arg Ala Trp Arg Val Gln Phe Ser Ser Ala Ile Gly Pro Tyr Lys
      80      85      90
GGC GGT ATG CGC TTC CAT CCG TCA GTT AAC CTT TCC ATT CTC AAA TTC 517
Gly Gly Met Arg Phe His Pro Ser Val Asn Leu Ser Ile Leu Lys Phe
50     95      100      105
CTC GGC TTT GAA CAA ACC TTC AAA AAT GCC CTG ACT ACT CTG CCG ATG 565
Leu Gly Phe Glu Gln Thr Phe Lys Asn Ala Leu Thr Thr Leu Pro Met
      110      115      120
GGC GGT GGT AAA GGC GGC AGC GAT TTC GAT CCG AAA GGA AAA AGC GAA 613
Gly Gly Gly Lys Gly Gly Ser Asp Phe Asp Pro Lys Gly Lys Ser Glu
55

```

EP 0 670 370 A2

		125				130				135					140		
		GGT	GAA	GTG	ATG	CGT	TTT	TGC	CAG	GCG	CTG	ATG	ACT	GAA	CTG	TAT	CGC
5		Gly	Glu	Val	Met	Arg	Phe	Cys	Gln	Ala	Leu	Met	Thr	Glu	Leu	Tyr	Arg
						145					150				155		661
		CAC	CTG	GGC	GCG	GAT	ACC	GAC	GTT	CCG	GCA	GGT	GAT	ATC	GGG	GTT	GGT
		His	Leu	Gly	Ala	Asp	Thr	Asp	Val	Pro	Ala	Gly	Asp	Ile	Gly	Val	Gly
					160					165					170		709
10		GGT	CGT	GAA	GTC	GGC	TTT	ATG	GCG	GGG	ATG	ATG	AAA	AAG	CTC	TCC	AAC
		Gly	Arg	Glu	Val	Gly	Phe	Met	Ala	Gly	Met	Met	Lys	Lys	Leu	Ser	Asn
					175				180					185			757
		AAT	ACC	GCC	TGC	GTC	TTC	ACC	GGT	AAG	GGC	CTT	TCA	TTT	GGC	GGC	AGT
		Asn	Thr	Ala	Cys	Val	Phe	Thr	Gly	Lys	Gly	Leu	Ser	Phe	Gly	Gly	Ser
							195					200					805
15		CTT	ATT	CGC	CCG	GAA	GCT	ACC	GGC	TAC	GGT	CTG	GTT	TAT	TTC	ACA	GAA
		Leu	Ile	Arg	Pro	Glu	Ala	Thr	Gly	Tyr	Gly	Leu	Val	Tyr	Phe	Thr	Glu
						210					215						853
		GCA	ATG	CTA	AAA	CGC	CAC	GGT	ATG	GGT	TTT	GAA	GGG	ATG	CGC	GTT	TCC
		Ala	Met	Leu	Lys	Arg	His	Gly	Met	Gly	Phe	Glu	Gly	Met	Arg	Val	Ser
						225					230					235	901
20		GTT	TCT	GGC	TCC	GGC	AAC	GTC	GCC	CAG	TAC	GCT	ATC	GAA	AAA	GCG	ATG
		Val	Ser	Gly	Ser	Gly	Asn	Val	Ala	Gln	Tyr	Ala	Ile	Glu	Lys	Ala	Met
						240				245					250		949
		GAA	TTT	GGT	GCT	CGT	GTG	ATC	ACT	GCG	TCA	GAC	TCC	AGC	GGC	ACT	GTA
		Glu	Phe	Gly	Ala	Arg	Val	Ile	Thr	Ala	Ser	Asp	Ser	Ser	Gly	Thr	Val
						255			260					265			997
25		GTT	GAT	GAA	AGC	GGA	TTC	ACG	AAA	GAG	AAA	CTG	GCA	CGT	CTT	ATC	GAA
		Val	Asp	Glu	Ser	Gly	Phe	Thr	Lys	Glu	Lys	Leu	Ala	Arg	Leu	Ile	Glu
						270		275				280					1045
		ATC	AAA	GCC	AGC	CGC	GAT	GGT	CGA	GTG	GCA	GAT	TAC	GCC	AAA	GAA	TTT
		Ile	Lys	Ala	Ser	Arg	Asp	Gly	Arg	Val	Ala	Asp	Tyr	Ala	Lys	Glu	Phe
						285		290				295				300	1093
30		GGT	CTG	GTC	TAT	CTC	GAA	GGC	CAA	CAG	CCG	TGG	TCT	CTA	CCG	GTT	GAT
		Gly	Leu	Val	Tyr	Leu	Glu	Gly	Gln	Gln	Pro	Trp	Ser	Leu	Pro	Val	Asp
						305					310					315	1141
		ATC	GCC	CTG	CCT	TGC	GCC	ACC	CAG	AAT	GAA	CTG	GAT	GTT	GAC	GCC	GCG
		Ile	Ala	Leu	Pro	Cys	Ala	Thr	Gln	Asn	Glu	Leu	Asp	Val	Asp	Ala	Ala
						320				325					330		1189
35		CAT	CAG	CTT	ATC	GCT	AAT	GGC	GTT	AAA	GCC	G					

EP 0 670 370 A2

	CCGGCAAAAT	TTCAGGCGTT	TATGAGTATT	TAACGGATGA	TGCTCCCCAC	GGAACATTTC	1694
5	TTATGGGCCA	ACGGCATTTC	TTACTGTAGT	GCTCCCAAAA	CTGCTTGTCG	TAACGATAAC	1754
	ACGCTTCAAG	TTCAGCATCC	GTAACTTTC	TGCGGACTCA	CGCGCGCAGC	ACTATGCCAG	1814
	TAAAGAAATC	CCATTTGACT	ATTTTTTTGA	TAATCTTCTT	CGCTTTCGAA	CAACTCGTGC	1874
	GCCTTTCGAG	AAGCAAGCAT	TATATAATGC	CAGGCCAGTT	CTTCTTCAAT	TGTCCCGTTT	1934
	TGA						1937
10							
15							
20							
25							
30							
35							
40							
45							
50							
55							

Claims

1. A mutant of the genus Escherichia having L-glutamic acid-productivity, said mutant having deficient or reduced α -ketoglutarate dehydrogenase activity and enhanced phosphoenolpyruvate carboxylase and glutamate dehydrogenase activities.
2. A method of producing L-glutamic acid by fermentation comprising culturing in a liquid culture medium a mutant of the genus Escherichia having L-glutamic acid-productivity said mutant having deficient or reduced α -ketoglutarate dehydrogenase activity and enhanced phosphoenolpyruvate carboxylase and glutamate dehydrogenase activities, accumulating L-glutamic acid in the culture, and recovering L-glutamic acid therefrom.

Fig.1




Fig.2





Fig.3



(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 670 370 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
28.05.1997 Bulletin 1997/22

(51) Int Cl.⁶: **C12N 15/52, C12P 13/14,**
C12N 1/21
// (C12N1/21, C12R1:19)

(43) Date of publication A2:
06.09.1995 Bulletin 1995/36

(21) Application number: **95100259.1**

(22) Date of filing: **10.01.1995**

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE
Designated Extension States:
LT SI

- Tsujimoto, Nobuharu, c/o Central Research Lab.
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)
- Matsui, Kazuhiko, c/o Central Research Lab.
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)
- Kurahashi, Osamu, c/o Central Research Lab.
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

(30) Priority: **10.01.1994 JP 825/94**

(71) Applicant: **Ajinomoto Co., Inc.**
Tokyo 104 (JP)

(74) Representative:
Strehl Schübel-Hopf Groening & Partner
Maximilianstrasse 54
80538 München (DE)

(72) Inventors:
• **Ono, Eiji, c/o Central Research Laboratories**
Kawasaki-ku, Kawasaki-shi, Kanagawa-ken (JP)

(54) Method of producing L-glutamic acid by fermentation

(57) The present invention provides a low-cost and efficient production method of L-glutamic acid, by improving the productivity of L-glutamic acid in a microorganism of the genus Escherichia.

[Constitution]

A method of producing L-glutamic acid by fermenta-

tation comprising culturing in a liquid culture medium a mutant of the genus Escherichia having L-glutamic acid-producing ability whose α -ketoglutarate dehydrogenase activity is deficient or reduced and phosphoenolpyruvate carboxylase and glutamate dehydrogenase activities are amplified, accumulating L-glutamic acid in the culture, and recovering L-glutamic acid therefrom.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 0259

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,A	FR 2 680 178 A (AJINOMOTO CO., INC.) 12 February 1993 * page 1, line 26 - page 3, line 8 * ---	1,2	C12N15/52 C12P13/14 C12N1/21 //(C12N1/21, C12R1:19)
A	EP 0 143 195 A (AJINOMOTO CO., INC.) 5 June 1985 * page 1, line 14 - page 4, line 14 * ---	1,2	
A	FR 2 575 492 A (ASAHI KASEI KOGYO KABUSHIKI KAISHA) 4 July 1986 * page 3, line 11 - line 33 * * page 7, line 9 - line 23 * -----	1,2	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12P
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 1 April 1997	Examiner Montero Lopez, B
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone V : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			